Legato Capital Management LLC Acquires 9,760 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Legato Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 122.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,755 shares of the company’s stock after purchasing an additional 9,760 shares during the period. Legato Capital Management LLC’s holdings in Tarsus Pharmaceuticals were worth $1,454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Federated Hermes Inc. lifted its stake in Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after acquiring an additional 339 shares during the last quarter. Valeo Financial Advisors LLC lifted its stake in Tarsus Pharmaceuticals by 11.1% in the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock valued at $321,000 after acquiring an additional 392 shares during the last quarter. Creative Planning lifted its stake in Tarsus Pharmaceuticals by 3.3% in the third quarter. Creative Planning now owns 12,367 shares of the company’s stock valued at $735,000 after acquiring an additional 393 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Tarsus Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock valued at $169,000 after acquiring an additional 431 shares during the last quarter. Finally, Comerica Bank lifted its stake in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after acquiring an additional 705 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $62.26 on Monday. The firm has a 50-day moving average of $66.07 and a 200-day moving average of $71.39. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. The stock has a market cap of $2.68 billion, a PE ratio of -54.61 and a beta of 0.52. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. The company had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -0.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, March 16th. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Guggenheim increased their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $90.67.

Insider Activity at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 4,174 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the sale, the insider owned 35,028 shares in the company, valued at approximately $2,346,876. This trade represents a 10.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Bryan Wahl sold 4,231 shares of the firm’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the sale, the general counsel owned 63,959 shares of the company’s stock, valued at approximately $4,285,253. This represents a 6.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 79,391 shares of company stock worth $5,432,035 in the last quarter. 9.64% of the stock is owned by corporate insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.